Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...

Selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK Observed complete responses in preclinical combination studies of Pol Theta Helicase DC with ...

A major pharmaceutical company is leaving behind more than half a million square feet in a suburb of Washington, D.C. when its lease expires next year. London-based GSK is set to depart 635,000 square ...

GSK (LSE:GSK) has completed its acquisition of RAPT Therapeutics, securing global rights to key immunology assets. The deal brings ozureprubart, a monoclonal antibody for severe food allergies, into ...

GSK on Wednesday agreed to pay $950 million in cash for Canadian biopharmaceutical company 35Pharma Inc, which is developing ...

Delve into the field of pulmonary hypertension as GSK places a $950M bet on 35Pharma's candidate HS235 following the footsteps of Winrevair.